The Journal
Immortality is not on the horizon. But for the first time, therapies designed to slow or reverse parts of ageing are being tested in people. Here is what is real, what is hype and what it means for aesthetics.
In 2026 a therapy built on David Sinclair's epigenetic reprogramming research was given to people for the first time, in an attempt to restore sight lost to glaucoma and optic nerve stroke. Here is what the early data shows.
NAD+ is the molecule at the centre of the longevity conversation. What it does, why levels fall with age, what the human evidence says and how clinics should talk about it.
